Mammary Cell News 10.01 January 11, 2018 | |
| |
TOP STORYDiscovery Could Help Treat Cancer More Effectively Researchers have discovered a mechanism that may make cancer cells more susceptible to treatment. Post-doctoral fellow Mohammad Ali and his research team found that the protein RYBP prevents DNA repair in cancer cells, including breast cancer, which in turn could make chemo or radiation therapy more effective. [Press release from the University of Alberta discussing online prepublication in Cell Reports] Press Release | Full Article | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists found a clear correlation between the presence of CD44v6/ErbB1 complexes in breast cancer patients and lymph node metastases. [Oncogene] Abstract Regulation of Mammary Luminal Cell Fate and Tumorigenesis by p38α Investigators showed that p38α regulates the fate of luminal progenitor cells through modulation of the transcription factor RUNX1, an important controller of the estrogen receptor-positive cell lineage. Using a mouse model for breast cancer initiated by luminal cells, they showed that p38α downregulation in mammary epithelial cells reduces tumor burden, which correlates with decreased numbers of tumor-initiating cells. [Stem Cell Reports] Full Article Researchers evaluated the efficacy of the antagonist of the SDF-1 receptor CXCR4, AMD3100, as a radiosensitizer in triple-negative breast cancer models. [Cancer Lett] Abstract The authors determined the role of miR-770 in the regulation of chemo-resistance and metastasis of triple negative breast cancer (TNBC). Clinically, miR-770 was highly expressed in chemo-sensitive tissues and predicted a better prognosis of TNBC. [Cell Death Dis] Full Article MDA-MB-231 breast cancer cells were engineered such that arylamine N-acetyltransferase 1 (NAT1) expression was elevated or suppressed, or treated with a small molecule inhibitor of NAT1. The MDA-MB-231 human breast cancer cell lines were engineered with a scrambled shRNA, a NAT1 specific shRNA or a NAT1 overexpression cassette stably integrated into a single flippase recognition target site facilitating incorporation of these different genetic elements into the same genomic location. [Mol Carcinog] Abstract TRAF2 in Osteotropic Breast Cancer Cells Enhances Skeletal Tumor Growth and Promotes Osteolysis Investigators report that stable overexpression of tumor necrosis factor receptor associated factor 2 (TRAF2) in parental and osteotropic sub-clones of human MDA-MB-231 breast cancer cells increased cell growth and motility in vitro, whereas TRAF2 knockdown was inhibitory. In vivo, TRAF2 overexpression in the parental MDA-231-P cells enhanced tumor growth after orthotopic injection into the mammary fat pad of mice but failed to promote the metastasis of these cells to bone. [Sci Rep] Full Article Blimp-1/PRDM1 Is a Critical Regulator of Type III Interferon Responses in Mammary Epithelial Cells Scientists report that Blimp-1 regulates expression of viral defense, interferon (IFN) signaling and MHC class I pathways, and directly targets the transcriptional activator Stat1. Blimp-1 functional loss in 3D cultures of mammary epithelial cells results in accumulation of dsRNA and expression of type III IFN-λ. [Sci Rep] Full Article Researchers evaluated the expression of CD10 in breast cancer and its association with the clinicopathological features. In addition, they investigated whether a relationship exists between CD10 expression and cancer stem cells. [BMC Cancer] Full Article Doxorubicin Resistance in Breast Cancer Cells Is Mediated by Extracellular Matrix Proteins Investigators utilized advanced breast cancer cell culture models to elucidate de novo doxorubicin resistance mechanisms. Breast cancer cells cultured in a 3D ECM-based model demonstrated altered sensitivity to doxorubicin, when compared to those grown in corresponding two-dimensional (2D) monolayer culture conditions. Investigations into the factors triggering the observed doxorubicin resistance revealed that cell-to-ECM interactions played a pivotal role. [BMC Cancer] Full Article The authors investigated the effects of HBXIP gene silencing on etoposide chemosensitivity in MCF-7 human breast cancer cells. They found that etoposide increases HBXIP expression and promotes mobilization of HBXIP to the nucleus in MCF-7 cells. [Gene] Abstract | |
| |
REVIEWSBreast Cancer Bone Metastases: Pathogenesis and Therapeutic Targets The authors discuss bone remodeling under normal physiological conditions and explore key pathways dysregulated in breast cancer metastasis to bone. They provide an overview of systemic therapies currently recommended for the treatment of breast cancer bone metastases and highlight emerging therapeutic targets. [Int J Biochem Cell Biol] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
SCIENCE NEWSH3 Biomedicine to Present 2018 Outlook H3 Biomedicine Inc. announced that it will outline its key 2018 strategies and goals that build upon its success in advancing three differentiated, internally generated cancer therapies into clinical trials. [Press release from H3 Biomedicine Inc. discussing research presented at the 36th Annual J.P. Morgan Healthcare Conference, San Francisco] Press Release Seattle Genetics Highlights Leadership in Expanding Field of Antibody-Drug Conjugates (ADCs) Seattle Genetics, Inc. highlighted the progress of its pipeline of antibody-drug conjugates (ADCs). Through both internal efforts and that of its collaborators, the company’s ADC technology is being employed in more than 20 programs in clinical trials, including multiple late-state development programs across hematologic malignancies and solid tumors. [Press release from Seattle Genetics discussing research presented at the 36th Annual J.P. Morgan Healthcare Conference, San Francisco] Press Release NantWorks to Present Healthcare and Biotechnology Platforms NantWorks, the parent organization of NantHealth and NantKwest announced that Dr. Patrick Soon-Shiong will present the current status of these companies and the overall ecosystem of NantWorks. Specific details will be presented regarding the current status of GPS Cancer™, including FDA filings and seminal patents issued covering tumor-normal analysis of DNA. [Press release from NantWorks (Business Wire, Inc.) discussing research presented at the 36th Annual J.P. Morgan Healthcare Conference, San Francisco] Press Release Syros to Present at 36th Annual J.P. Morgan Healthcare Conference Syros Pharmaceuticals announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview, including 2018 objectives. [Press release from Syros Pharmaceuticals discussing research presented at the 36th Annual J.P. Morgan Healthcare Conference, San Francisco] Press Release | |
| |
INDUSTRY NEWSSyndax Pharmaceuticals, Inc. announced a new clinical collaboration with Genentech, a member of the Roche Group. As part of the collaboration, the two companies will evaluate the combination of Syndax’s entinostat, an oral, small molecule, class I HDAC inhibitor, and Genentech’s programmed cell death ligand 1 blocking antibody, atezolizumab, in patients with second-line hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+, HER2–) metastatic breast cancer. [Syndax Pharmaceuticals, Inc.] Press Release Yorkshire Cancer Research Announces £3.6M Investment in New Research Projects Yorkshire Cancer Research will invest £3.6m in eight new research projects to help improve the prevention, diagnosis and treatment of cancer in Yorkshire. [Yorkshire Cancer Research] Press Release | |
| |
POLICY NEWSRising Star Appointed UK Science Minister The United Kingdom has gained a new science minister as part of a broader reshuffle of government posts. Sam Gyimah, who moves from the Ministry of Justice, was appointed minister for universities and science, replacing Jo Johnson. [Nature News] Editorial Faced with Public Pressure, Research Institutions Step Up Reporting of Clinical Trial Results The reporting of clinical trial results to a public database — mandated by a ten-year-old federal law — has improved sharply in the last two years, with universities and other nonprofit research centers leading the way. [STAT News] Editorial Koch-Backed Groups Urge Congress to Pass Right-to-Try Legislation Several deep-pocketed political advocacy groups founded by Charles and David Koch are ramping up their advocacy before Congress on a niche issue: access to experimental drugs. [STAT News] Editorial
| |
EVENTSNEW Canadian Breast Cancer Symposium 2018 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Training Fellow – Molecular Engineering (The Institute of Cancer Research) Scientific Officer – Breast Cancer Research (The Institute of Cancer Research) Higher Scientific Officer – Breast Cancer Research (The Institute of Cancer Research) Postdoctoral Associate – Breast Cancer Research (University of Miami) PhD Program – Breast Cancer (Institut Curie) Professor – Tenure System – Cancer Biology (Michigan State University) Postdoctoral Associate – Breast Cancer Research (University of Miami) Postdoctoral Associate – Melanoma and Breast Cancer Research (University of Miami) Postdoctoral Fellowship – Breast Cancer Research (Geisel School of Medicine at Dartmouth) Postdoctoral Position – Transcriptomics and Cancer Epigenetics (Universität Basel) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|